Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Infect Dis Obstet Gynecol ; 2020: 7201840, 2020.
Article in English | MEDLINE | ID: mdl-32410819

ABSTRACT

Purpose: A novel fixed-dose combination of 150 mg of econazole with 6 mg of benzydamine formulated in vaginal ovules was investigated in a randomised, double-blind, four-parallel group, tolerability, and pharmacokinetic Phase I study in healthy women. Methods: The fixed-dose combination was compared to econazole and benzydamine single-drug formulations and with placebo after daily applications for 3 consecutive days. Safety and tolerability were evaluated recording the adverse drug reactions, local and general tolerability scores, clinical laboratory assays, and vital signs. Econazole, benzydamine, and its metabolite benzydamine N-oxide pharmacokinetics were investigated after single and multiple applications. Results: Local reactions were generally absent. Pruritus and pain at the application site were infrequently reported. According to the subjects' evaluations, the overall tolerability of the ovules was rated as excellent or good. No significant effect of any treatment on laboratory parameters, vital signs, body weight, vaginal pH, or ECG was observed. Very low econazole, benzydamine, and benzydamine-N-oxide concentrations were measured in plasma, though quantifiable in almost all samples. Conclusion: The tested fixed-dose combination showed a good safety profile consistently with the known tolerability of both active substances. In addition, the confirmed low bioavailability of the drugs excludes the possibility of any accumulation effects and limits the risk of undesired systemic effects. This trial is registered at ClinicalTrials.gov with the identifier NCT02720783 last updated on 07 February 2017.


Subject(s)
Antifungal Agents/pharmacokinetics , Benzydamine/pharmacokinetics , Drug Delivery Systems/instrumentation , Econazole/pharmacokinetics , Vagina/drug effects , Administration, Oral , Adult , Antifungal Agents/administration & dosage , Area Under Curve , Benzydamine/administration & dosage , Benzydamine/analogs & derivatives , Double-Blind Method , Drug Administration Schedule , Drug Combinations , Econazole/administration & dosage , Female , Healthy Volunteers , Humans , Middle Aged , Young Adult
2.
Boll Chim Farm ; 131(1): 22-9, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1622607

ABSTRACT

The purpose of this study was to validate an analytical method for the determination of bendazac and its main metabolite 5-hydroxybendazac in human plasma. The results obtained indicate that the method is reproducible, accurate, precise, sensitive and specific for the measurement of bendazac and 5-hydroxybendazac in the human plasma. Therefore it can be considered suitable for experimental purposes, routine application for drug monitoring and regulatory requirements.


Subject(s)
Indazoles/blood , Chromatography, High Pressure Liquid , Humans , Spectrophotometry, Ultraviolet
3.
Boll Chim Farm ; 130(11): 449-57, 1991 Dec.
Article in English | MEDLINE | ID: mdl-1809299

ABSTRACT

The purpose of this study was to validate an analytical method for the determination of bendazac and its main metabolite 5-hydroxybendazac in aqueous humor. The method was validated with rabbit aqueous but it can be used also for human aqueous since no differences between the two matrices were observed. The results obtained indicate that the method is reproducible, accurate, precise, sensitive and specific for the measurement of bendazac and 5-hydroxybendazac in the aqueous humor. Therefore it can be considered suitable for experimental purposes, drug monitoring and adequate for regulatory requirements.


Subject(s)
Aqueous Humor/chemistry , Indazoles/analysis , Animals , Chromatography, High Pressure Liquid , Humans , Rabbits
4.
Semin Oncol ; 18(2 Suppl 4): 11-7, 1991 Apr.
Article in English | MEDLINE | ID: mdl-2031191

ABSTRACT

The plasma levels of lonidamine have been studied in 24 breast or lung cancer patients as part of the Phase II evaluation of the drug. The pharmacokinetic studies were performed when the patients had been on oral lonidamine therapy for 27 to 47 days (mean 32 days) and the studies were conducted over a 24 hour period. Lonidamine was administered in three divided doses of 150 mg (t = 0h), 150 mg (t = 7h), and 150 mg or 300 mg (t = 14h). Plasma levels of lonidamine were determined by high-performance liquid chromatography (HPLC) with fluorescence detection. Lonidamine was detected in the plasma of all patients studied, and the absolute range for the peak plasma levels of the drug following the first and second doses were 4.6-33.8 and 4.8-33.3 micrograms/ml, respectively. The range of times after administration at which the peak occurred was 0.5 to 4.2 hours for the first dose and 0.5 to 4.1 hours for the second. The absolute range for the trough levels observed over the 24-hour study period was 1.0 to 12.6 micrograms/ml and in 19 of the patients it was possible to define the apparent half life of lonidamine that was found to be within the range 2.5 to 11.7 hours. In addition to lonidamine, a number of fluorescent components were detected in the plasma of patients following lonidamine treatment that were not detected in pretreatment plasma samples. One component, a compound that eluted from the HPLC more rapidly than lonidamine, was found in some patients to be sensitive to hydrolysis with beta-glucuronidase. Comparison of the pharmacokinetic data with patient characteristics and clinical biochemistry results failed to establish any clear relationship. Similarly there was no relationship between lonidamine pharmacokinetics and either drug-induced myalgia or testicular pain. Insufficient responses were seen in the patient group studied to allow the relationship between lonidamine pharmacokinetics and response to be evaluated.


Subject(s)
Antineoplastic Agents/pharmacokinetics , Breast Neoplasms/drug therapy , Indazoles/pharmacokinetics , Lung Neoplasms/drug therapy , Absorption , Administration, Oral , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/blood , Antineoplastic Agents/therapeutic use , Chromatography, High Pressure Liquid , Drug Administration Schedule , Drug Tolerance , Female , Fluorescence , Humans , Indazoles/administration & dosage , Indazoles/blood , Indazoles/therapeutic use , Male , Middle Aged , Tablets , Time Factors
5.
Arzneimittelforschung ; 41(4): 436-9, 1991 Apr.
Article in English | MEDLINE | ID: mdl-1650226

ABSTRACT

Pharmacokinetic studies of lonidamine (1-[2,4-dichlorobenzyl]- 1H- indazole- 3-carboxylic acid, Doridamina: CAS 50264-69-2) in humans showed a wide variation of the plasma concentration-time profiles following a single peroral dose of 300 mg (Cmax between 6.5 and 40.9 micrograms/ml, tmax between 0.75 and 5.5 h). In order to investigate single and multiple dose pharmacokinetics after peroral administration of this chemotherapeutic compound, a study was performed involving 12 patients with non-small-cell malignancies of the lungs. Plasma and urinary concentration profiles were analyzed for determination of the pharmacokinetic parameters for lonidamine after single dose administration and in the steady state. In addition, age dependency and the presence of liver induction or inhibition was evaluated. Results indicate that steady state was reached after 2 dosing intervals of 12 h and no changes in liver metabolism or age dependent pharmacokinetics could be revealed after 4 days of multiple dose treatment.


Subject(s)
Antineoplastic Agents/pharmacokinetics , Carcinoma, Non-Small-Cell Lung/metabolism , Indazoles/pharmacokinetics , Lung Neoplasms/metabolism , Adult , Aged , Aging/metabolism , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Chromatography, Gas , Chromatography, High Pressure Liquid , Female , Humans , Indazoles/adverse effects , Indazoles/therapeutic use , Liver/metabolism , Lung Neoplasms/drug therapy , Male , Middle Aged
8.
Pharmacol Res Commun ; 18(4): 385-403, 1986 Apr.
Article in English | MEDLINE | ID: mdl-3737653

ABSTRACT

A method for the extraction and quantification of benzydamine and its metabolite N-oxide by liquid chromatography with fluorescence detection in plasma samples is described. This method has adequate sensitivity, specificity and is reproducible. The use of the extraction column allowed a recovery of both benzydamine and its metabolite of over 97% to be obtained. The plasma levels of benzydamine and its metabolite N-oxide were studied after oral administration as sugar-coated tablets or topical application to the vaginal mucosa as a cream to 6 healthy volunteers. After topical application, the plasma concentrations of the unchanged drug and its metabolite are lower than those obtained following oral administration. These data further stress the concept that, whenever possible, topical use should be considered the treatment of choice since, along with a more selective therapy, the incidence of systemic side effects can be considerably reduced.


Subject(s)
Anti-Inflammatory Agents/blood , Benzydamine/blood , Pyrazoles/blood , Administration, Oral , Administration, Topical , Adult , Aged , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/metabolism , Benzydamine/administration & dosage , Benzydamine/analogs & derivatives , Benzydamine/metabolism , Chromatography, High Pressure Liquid , Female , Humans , Kinetics , Male , Middle Aged , Spectrometry, Fluorescence
SELECTION OF CITATIONS
SEARCH DETAIL
...